By investigating these patterns, this study seeks to clarify whether SH3YL1 can serve as a reliable biomarker for both kidney injury and bladder cancer progression, specifically in the context of cisplatin therapy. This evidence concerns the gene SH3YL1 and urinary bladder cancer.